Congenital adrenal hyperplasia
MONDO:0018479Congenital adrenal hyperplasia (CAH) is an inherited endocrine disorder caused by a steroidogenic enzyme deficiency that is characterized by adrenal insufficiency and variable degrees of hyper or hypo androgyny manifestations, depending of the type and the severity of the disease.
Also known as: adrenal hyperplasia, adrenogenital disorder, adrenogenital syndrome, CAH, adrenal hyperplasia, congenital, congenital adrenal gland hyperplasia, congenital lipoid adrenal hyperplasia, lipoid CAH
40 clinical trials for this condition and its sub-types, 36 tagged with Congenital adrenal hyperplasia itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Congenital adrenal hyperplasia
-
Can a modified hydrocortisone mimic the Body's natural cortisol rhythm?
Disease control CompletedResearchers are testing Chronocort, a modified-release form of hydrocortisone, against standard immediate-release hydrocortisone in 30 healthy male volunteers. The study measures how the drug moves through the body, including how fast it reaches peak levels and how long it stays …
Phase 1 • Sponsor: Neurocrine UK Limited • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Can a Timed-Release hydrocortisone pill match the Body's overnight hormone rhythm?
Disease control CompletedResearchers are testing several modified, timed-release versions of hydrocortisone, a hormone drug, in healthy male volunteers. The study has two parts: one compares how six different formulations move through the body after a single nighttime dose, and the other checks whether t…
Phase 1 • Sponsor: Neurocrine UK Limited • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New pill could tame rare hormone disorder
Disease control CompletedThis study tested a new oral drug called atumelnant in 38 adults with classic congenital adrenal hyperplasia, a genetic condition causing hormone imbalances. The drug works by blocking a hormone receptor to lower excess adrenal hormones. Researchers measured safety, side effects,…
Phase 2 • Sponsor: Crinetics Pharmaceuticals Inc. • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New hormone treatment shows promise for rare adrenal disorder
Disease control CompletedThis study looked at the long-term safety of a medication called Chronocort in 76 people aged 16 and older with congenital adrenal hyperplasia (CAH), a condition where the body can't make enough cortisol. Researchers monitored for signs of over- or under-treatment, adrenal crises…
Phase 3 • Sponsor: Immedica Pharma AB • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug shows promise for rare hormone disorder
Disease control CompletedThis phase 2 trial tested a new drug called SPR001 in 24 adults with classic congenital adrenal hyperplasia (CAH), a genetic condition that disrupts hormone production. The study aimed to see if SPR001 is safe and can improve hormone control. Participants took multiple doses of t…
Phase 2 • Sponsor: Spruce Biosciences • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Italian study checks how well newborn screening detects rare hormone disorder
Knowledge-focused CompletedThis completed study looked at newborn screening for congenital adrenal hyperplasia (CAH) in Italy. Researchers reviewed medical records of 29 infants diagnosed with classic CAH between 2006 and 2019 to see how accurate the screening was. The goal was to measure the screening's s…
Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC
-
Prenatal steroid for CAH: safe for the brain? new study investigates
Knowledge-focused CompletedThis study evaluates the long-term cognitive development of children who were exposed to dexamethasone (a steroid) while in the womb because they were at risk for congenital adrenal hyperplasia (CAH). The goal is to see if the drug causes any thinking or memory problems. Research…
Sponsor: Hospices Civils de Lyon • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC
-
Rare enzyme Disorder's blood pressure mystery probed
Knowledge-focused CompletedThis completed study investigated why patients with Cytochrome P450 Oxidoreductase (POR) deficiency, a rare genetic condition, often develop high blood pressure and blood vessel damage. Researchers compared 51 participants (patients and healthy controls) using 24-hour blood press…
Sponsor: Ozge Bayrak Demirel • Aim: Knowledge-focused
Last updated Jun 26, 2026 14:41 UTC